"The number of children living in the United States declined slightly, as did the percentage of the U.S. population who are children, according to the federal government's annual statistical report on the well-being of the nation's children and yo"...
Ceredase® (alglucerase injection) is indicated for use as long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions:
- moderate-to-severe anemia;
- thrombocytopenia with bleeding tendency;
- bone disease;
- significant hepatomegaly or splenomegaly.
DOSAGE AND ADMINISTRATION
Ceredase® (alglucerase injection) is administered by intravenous infusion over 1-2 hours. Dosage should be individualized for each patient. Initial dosage may be as little as 2.5 units/kg of body weight 3 times a week up to as much as 60 units/kg administered as frequently as once a week or as infrequently as every 4 weeks. 60 units/kg every 2 weeks is the dose for which the most data are available. Disease severity may dictate that drug be initiated with relatively high doses or relatively frequent administration. After patient response is well-established, a reduction in dosage may be attempted for maintenance therapy. Progressive reductions can be made at intervals of 3-6 months while carefully monitoring response parameters.
Ceredase® (alglucerase injection) should not be shaken. Each bottle should be inspected visually for particulate matter and discoloration before use. Any bottles exhibiting particulate matter or discoloration should not be used. DO NOT USE Ceredase® (alglucerase injection) after the expiration date on the bottle.
On the day of use, the appropriate amount of Ceredase® (alglucerase injection) for each patient is diluted with 0.9% sodium chloride IV solution to a final volume not to exceed 200 mL. Aseptic techniques should be used when diluting the dose. Ceredase® (alglucerase injection) , when diluted to 100 to 200 mL, has been shown to be stable for up to 18 hours when stored at 2 - 8°C. The use of an in-line particulate filter is recommended for the infusion apparatus. Since Ceredase® (alglucerase injection) does not contain any preservative, after opening, bottles should not be stored for subsequent use.
Relatively low toxicity, combined with the extended time course of response, allows small dosage adjustments to be made occasionally to avoid discarding partially used bottles. Thus, the dosage administered in individual infusions may be slightly increased or decreased to utilize fully each bottle as long as the monthly administered dosage remains substantially unaltered.
Ceredase® (alglucerase injection) is supplied as a clear sterile citrate buffered solution (53 mM citrate, 143 mM sodium) containing 1% albumin human USP. The following package is available: -The 400 unit bottle contains 5 mL in a 10 mL glass bottle. NDC 58468-1060-1. Store at 2 - 8°C.
Ceredase® (alglucerase injection) is manufactured by:
Genzyme Corporation, 500 Kendall Square, Cambridge, MA 02142. REV 10/04. FDA Rev date: 2/9/2006This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/28/2009
Additional Ceredase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Parenting and Pregnancy
Get tips for baby and you.